Related references
Note: Only part of the references are listed.Detection of microsatellite instability in a panel of solid tumours with the Idylla MSI Test using extracted DNA
Adrien Pecriaux et al.
JOURNAL OF CLINICAL PATHOLOGY (2021)
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
Courtney D. DiNardo et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The implications of IDH mutations for cancer development and therapy
Christopher J. Pirozzi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Evaluation of the Idylla system to detect the EGFRT790M mutation using extracted DNA
Claire Bocciarelli et al.
PATHOLOGY RESEARCH AND PRACTICE (2020)
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma
William D. Tap et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Development of a Rapid and Sensitive IDH1/2 Mutation Detection Method for Glial Tumors and a Comparative Mutation Analysis of 236 Glial Tumor Samples
Timucin Avsar et al.
MOLECULAR DIAGNOSIS & THERAPY (2020)
Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma
Ingo K. Mellinghoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
Michael Heuser et al.
LEUKEMIA (2020)
Outcome of patients with IDH1/2-mutated post myeloproliferative neoplasm AML in the era of IDH inhibitors
Helen T. Chifotides et al.
BLOOD ADVANCES (2020)
FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation
Kelly J. Norsworthy et al.
CLINICAL CANCER RESEARCH (2019)
Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review
Audra N. Boscoe et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)
Biological Role and Therapeutic Potential of IDH Mutations in Cancer
Matthew S. Waitkus et al.
CANCER CELL (2018)
Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group
Yann Ferret et al.
HAEMATOLOGICA (2018)
Multiple Ways to Detect IDH2 Mutations in Angioimmunoblastic T-Cell Lymphoma from Immunohistochemistry to Next-Generation Sequencing
Aurelie Dupuy et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group
Yann Ferret et al.
HAEMATOLOGICA (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Isocitrate dehydrogenase mutations in myeloid malignancies
B. C. Medeiros et al.
LEUKEMIA (2017)
DNA degrades during storage in formalin-fixed and paraffin-embedded tissue blocks
Alice Guyard et al.
VIRCHOWS ARCHIV (2017)
The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development
Francois Lemonnier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma
Chao Wang et al.
BLOOD (2015)
Rapid Intraoperative Molecular Characterization of Glioma
Ganesh M. Shankar et al.
JAMA ONCOLOGY (2015)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities
Rob A. Cairns et al.
CANCER DISCOVERY (2013)
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma
Rob A. Cairns et al.
BLOOD (2012)
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lu et al.
NATURE (2012)
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
M. Fernanda Amary et al.
JOURNAL OF PATHOLOGY (2011)
IDH1R132 mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain
Giselle Y. Lopez et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas
Jefferson Pessoa Hemerly et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers
Mi Ran Kang et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
The consensus coding sequences of human breast and colorectal cancers
Tobias Sjoeblom et al.
SCIENCE (2006)
Share Paper
